A study found that cetuximab has the potential to induce ADCC against EGFR-expressing lung cancer cells.[15] Another study showed that necitumumab could inhibit EGFR-dependent tumor cell proliferation and exert cytotoxic effects on tumor cells via ADCC.[28] Therefore, it is reasonable to assume that patients with squamous NSCLC may benefit more from anti-EGFR-mAb therapy than other NSCLC patients because these antibodies are known to induce ADCC. The gene discussed is EGFR; the disease is lung carcinoma.